$VNOV · VitaNova Life Sciences Corp
VitaNova Life Sciences Corp filed its 10-Q for Q1 FY2027 (ended July 31, 2026). Revenue grew 209.5% YoY to $321,576, driven by the new healthy food products segment launched via subsidiary VitaNova Global Foods. However, cost of revenue surged 729% to $291,055, compressing gross margin to 9.5% from 66% a year ago. Net loss widened to $123,101 (-$0.01/share) from $46,301. The dietary supplement segment generated $87,000 in revenue at 27% gross margin, while the new food segment produced $234,576 at just 3% gross margin due to promotional pricing.
- Revenue surged 209.5% YoY to $321,576, driven by new healthy food product line (olive juice, sesame oil, aloe vera drinks).
- Gross margin collapsed to 9.5% from 66% YoY — cost of revenue jumped 729% to $291,055, consuming nearly all revenue.
- Net loss widened to $123,101 from $46,301 YoY; operating margin deteriorated to -38.0%.
- Three customers accounted for 91% of Q1 revenue ($291,600), with zero accounts receivable — extreme concentration risk.
- Cash remains at $1.6M with no debt, but operating cash flow dwindled to just $6,965 vs. $263,811 a year ago.
Price data unavailable.
A 209% revenue surge paired with a margin collapse from 66% to 9.5% signals a fundamentally broken business model pivot that is destroying shareholder value.
Micro-cap health-and-wellness distributors often pivot into adjacent product categories to scale revenue, but the 9.5% gross margin is well below industry norms for branded CPG and suggests the company is buying market share through discounting.
Extreme customer concentration: three customers represent 91% of Q1 revenue. Gross margin erosion from 66% to 9.5% suggests the new food product strategy is unprofitable at current pricing. Operating cash flow nearly vanished ($6,965 vs. $263,811 YoY).
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.